Table 2. Numbers of reported adverse events (AE) following the COVID-19 inactivated vaccine (CoronaVac) in the elderly and proportions of events per contacted participants, according to dose. Sao Paulo, 2021.

	1st dose		2nd dose
	Number of reported AE / Number of contacted participants	%	Number of reported AE / Number of contacted participants	%
Solicited local AE	21/151	13.91	6/141	4.26
Pain	13/150	8.67	5/141	3.55
Erythema	2/151	1.33	0/141	0
Swelling	2/151	1.33	0/141	0
Induration	1/151	0.66	1/141	0.71
Pruritus	3/151	1.99	0/140	0
Solicited systemic AE	48/151	31.79	49/141	34.75
Fever	0/151	0	2/141	1.42
Chills	4/151	2.65	2/141	1.42
Fatigue	9/150	6.00	8/138	5.80
Headache	6/150	4.00	6/138	4.34
Myalgia	5/150	3.33	10/138	7.24
Arthralgia	2/151	1.33	0/138	0
Nausea	5/150	3.33	6/138	4.34
Diarrhea	6/151	3.97	3/141	2.13
Vomiting	2/151	1.33	2/141	1.42
Anorexia	3/150	2.00	7/139	5.04
Pruritus	6/151	3.97	3/139	2.16
Solicited AE	69	-	55	-
Unsolicited AE	n	% of contacted	N	% of contacted
Unsolicited AE	18	-	19	-
Drowsiness	3	1.99	3	2.13
Dizziness	1	0.66	2	1.42
Sweating	0	0	2	1.42
Pallor	0	0	1	0.71
Cough	2	1.33	2	1.42
Hoarseness	0	0	1	0.71
Flu-like symptoms	0	0	1	0.71
Arm pain	1	0.66	0	0
Bruise	1	0.66	0	0
Injection site bleeding	0	0	1	0.71
Painful adenomegaly	1	0.66	0	0
Abdominal pain	0	0	1	0.71
Seizures	1	0.66	1	0.71
Syncope	1	0.66	0	0
Anemia	1	0.66	0	0
Pneumonia	1	0.66	0	0
Urinary infection	2	1.33	0	0
Stroke	2	1.33	3	2.13
Death	2	1.33	0	0
Total reported AE	88	-	73	-
Severe AE	5*		3**
COVID-19	1		1

*Severe AE following the 1^st dose: Emergency Room visit (2), hospitalization (1), deaths (2); **Severe AE following the 2^nd dose: hospitalization (3)